JINGXIN(SZ:002020)2023-05-23 06:06Group 1: Company Overview - Zhejiang Jingxin Pharmaceutical Co., Ltd. reported a revenue of 3.78 billion in 2022, representing a year-on-year growth of 9.04% [2] - The net profit attributable to shareholders for 2022 was 662 million, with an increase of 8.12% [2] - In Q1 2023, the company achieved a revenue of 960 million, reflecting a growth of 7.03% [2] Group 2: Business Segments - The company operates in three main business segments: finished drugs, raw materials, and medical devices [2] - Finished drugs accounted for approximately 60% of total revenue in 2022, with sales revenue from the CNS pipeline reaching 570 million [3] Group 3: Future Development - Future R&D efforts will focus on both replacing and supplementing existing product lines, addressing unmet clinical needs in the CNS sector [4]